Pronidesivir (GS-441524) Package Insert
Pronidesivir (GS-441524), marketed as NeoFipronis, is a groundbreaking oral antiviral medication specifically designed for the treatment of Feline Infectious Peritonitis (FIP). Approved in March 2026 by the Lao Ministry of Agriculture and Forestry (MAF), NeoFipronis represents the world’s first officially registered FIP-specific oral therapy, providing a safe, non-invasive, and highly effective treatment option for affected cats.
FIP is a severe, often fatal disease caused by a mutated feline coronavirus leading to a range of clinical symptoms including loss of appetite, lethargy, fever, abdominal and thoracic fluid accumulation, lymphadenopathy, granulomatous inflammation, neurological deficits, and uveitis. Conventional treatments have historically been limited, making NeoFipronis a significant advancement in feline medicine.
The active ingredient in NeoFipronis is GS-441524, a nucleoside analog that interferes with viral RNA replication. Extensive research and clinical trials have validated its potent antiviral activity, leading to remarkable cure rates in cats diagnosed with various forms of FIP, including effusive, neurological, and ocular types. The medication’s high bioavailability ensures rapid absorption, leading to swift onset of action, and its safety profile exhibits minimal adverse effects, making it suitable for long-term therapy.
Usage and Dosage:
The recommended dosage of NeoFipronis is based on the cat’s body weight. Administer 15 mg per kilogram of body weight once daily (approximately half a tablet). For cats with neurological or ocular forms of FIP, the dose should be incremented to 30 mg/kg, following veterinarian guidance. Administer the medication on an empty stomach—either one hour before feeding or two hours after—to maximize absorption. The treatment course should continue uninterrupted for no less than 12 weeks to ensure complete viral clearance and reduce relapse risk.
Monitoring and Precautions:
During treatment, monitor cats closely for changes in appetite, body temperature, and behavior. Regular blood tests should be performed to evaluate liver and kidney function, ensuring the medication’s safety over the extended treatment period. Although NeoFipronis is available OTC, veterinary supervision is highly recommended to tailor dosage and monitor progress.
Safety and Regulatory Notes:
NeoFipronis is approved exclusively for feline use. It is not suitable for humans or other animals. Always obtain NeoFipronis through official channels via the NeoFipronis official website to guarantee authenticity and quality. Adherence to the prescribed regime and veterinary advice is crucial to prevent underdosage, resistance development, and adverse effects.
Important Warnings:
Use strictly for cats diagnosed with FIP.
Do not administer to pregnant or lactating cats without veterinary consultation.
Complete the full treatment course as prescribed. Missing doses may compromise efficacy and promote resistance.
Regular veterinary follow-ups are essential for safe and effective therapy.
Conclusion
NeoFipronis (Pronidesivir) offers a safe, effective, and easy-to-administer treatment for FIP, drastically improving prognosis for affected cats. Its proven antiviral effect, combined with excellent tolerability and minimal side effects, makes it the treatment of choice in feline medicine. Owners should work closely with veterinarians to ensure optimal outcomes and monitor health throughout the treatment process. For authentic products, always book via the official NeoFipronis website, ensuring safety and quality in feline FIP management.
